These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

946 related items for PubMed ID: 25721091

  • 1. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
    Kwon J, Kim IH, Kim BH, Kim TM, Heo DS.
    Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):91-8. PubMed ID: 25721091
    [Abstract] [Full Text] [Related]

  • 2. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS.
    J Clin Oncol; 2010 Sep 20; 28(27):4170-6. PubMed ID: 20713859
    [Abstract] [Full Text] [Related]

  • 3. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):569-77. PubMed ID: 23540349
    [Abstract] [Full Text] [Related]

  • 4. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B.
    Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):122-9. PubMed ID: 25754633
    [Abstract] [Full Text] [Related]

  • 5. Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma.
    Yu JI, Nam H, Ahn YC, Kim WS, Park K, Kim SJ.
    Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):507-12. PubMed ID: 20056353
    [Abstract] [Full Text] [Related]

  • 6. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Lancet; 2013 May 25; 381(9880):1817-26. PubMed ID: 23615461
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2008 May 25; 9(5):435-44. PubMed ID: 18400558
    [Abstract] [Full Text] [Related]

  • 8. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.
    Ann Hematol; 2012 Jun 25; 91(6):837-45. PubMed ID: 22160255
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A, Lunning MA, Zhang Z, Migliacci JC, Moskowitz CH, Zelenetz AD.
    Br J Haematol; 2015 Dec 25; 171(5):776-83. PubMed ID: 26456939
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
    Ueda K, Yokoyama M, Asai H, Koudaira M, Yamada S, Katsube A, Mishima Y, Sakajiri S, Takeuchi K, Saotome T, Terui Y, Takahashi S, Hatake K.
    Gan To Kagaku Ryoho; 2010 May 25; 37(5):853-7. PubMed ID: 20495315
    [Abstract] [Full Text] [Related]

  • 15. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH, Kim JW, Jeon YW, Lee SE, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Min WS, Park CW, Cho SG.
    Korean J Intern Med; 2015 May 25; 30(3):362-71. PubMed ID: 25995667
    [Abstract] [Full Text] [Related]

  • 16. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2011 Oct 25; 12(11):1013-22. PubMed ID: 21940214
    [Abstract] [Full Text] [Related]

  • 17. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
    Song MK, Chung JS, Lee GW, Cho SH, Hong J, Shin DY, Shin HJ.
    Leuk Res; 2015 Feb 25; 39(2):211-5. PubMed ID: 25541029
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
    Lee HS, Park LC, Lee EM, Shin SH, Ye BJ, Oh SY, Song MK, Lee SM, Lee WS, Kang BW, Chang MH, Cho SG, Yahng SA, Yoon SS, Kwon JH, Kim YS.
    Am J Clin Oncol; 2014 Apr 25; 37(2):182-7. PubMed ID: 23211226
    [Abstract] [Full Text] [Related]

  • 20. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.
    J Clin Oncol; 2015 Jan 20; 33(3):251-7. PubMed ID: 25135992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.